Pivampicillin-promoted excretion of pivaloylcarnitine in humans

B. Melegh, Janos Kerner, Loran L. Bieber

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Pivampicillin treatment of seven children (five boys and two girls) for 7 days significantly reduced the amounts of total acid-soluble carnitine, free carnitine, and long-chain acylcarnitines and increased the amounts of acid-soluble acylcarnitine in plasma. The fasting plasma levels of 3-hydroxybutyrate at the end of treatment were 15% of the control value. The levels of free tatty acids were decreased, whereas triglyceride levels were unaffected, indicating impaired fat metabolism. Daily urinary excretion of total carnitine was four to five times higher than controls after the first day of treatment, although the amounts of free carnitine and acetylcarnitine were decreased. The urinary acylcarnitines were isolated and characterized by gas chromatography/electron impact mass spectrometry and fast-atom bombardment mass spectrometry. Pivaloylcarnitine was the predominant urinary acylcarnitine; it represented > 96% of the increased excretion of total carnitine and 75-80% of the total conjugated pivalic acid. The renal clearance of acylcarnitines was comparable to that of creatinine, indicating no reabsorption of pivaloylcarnitine. These data suggest a detoxification function of carnitine for pivalic acid in humans.

Original languageEnglish
Pages (from-to)3405-3409
Number of pages5
JournalBiochemical Pharmacology
Volume36
Issue number20
DOIs
Publication statusPublished - Oct 15 1987

Fingerprint

Pivampicillin
Carnitine
Acids
Mass spectrometry
Acetylcarnitine
Fast Atom Bombardment Mass Spectrometry
Plasmas
Detoxification
3-Hydroxybutyric Acid
Metabolism
Gas chromatography
Gas Chromatography
pivaloylcarnitine
Fasting
Mass Spectrometry
Creatinine
Triglycerides
Therapeutics
Fats
acylcarnitine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pivampicillin-promoted excretion of pivaloylcarnitine in humans. / Melegh, B.; Kerner, Janos; Bieber, Loran L.

In: Biochemical Pharmacology, Vol. 36, No. 20, 15.10.1987, p. 3405-3409.

Research output: Contribution to journalArticle

Melegh, B. ; Kerner, Janos ; Bieber, Loran L. / Pivampicillin-promoted excretion of pivaloylcarnitine in humans. In: Biochemical Pharmacology. 1987 ; Vol. 36, No. 20. pp. 3405-3409.
@article{63782396c2e742abbc4c8e921efa0e6d,
title = "Pivampicillin-promoted excretion of pivaloylcarnitine in humans",
abstract = "Pivampicillin treatment of seven children (five boys and two girls) for 7 days significantly reduced the amounts of total acid-soluble carnitine, free carnitine, and long-chain acylcarnitines and increased the amounts of acid-soluble acylcarnitine in plasma. The fasting plasma levels of 3-hydroxybutyrate at the end of treatment were 15{\%} of the control value. The levels of free tatty acids were decreased, whereas triglyceride levels were unaffected, indicating impaired fat metabolism. Daily urinary excretion of total carnitine was four to five times higher than controls after the first day of treatment, although the amounts of free carnitine and acetylcarnitine were decreased. The urinary acylcarnitines were isolated and characterized by gas chromatography/electron impact mass spectrometry and fast-atom bombardment mass spectrometry. Pivaloylcarnitine was the predominant urinary acylcarnitine; it represented > 96{\%} of the increased excretion of total carnitine and 75-80{\%} of the total conjugated pivalic acid. The renal clearance of acylcarnitines was comparable to that of creatinine, indicating no reabsorption of pivaloylcarnitine. These data suggest a detoxification function of carnitine for pivalic acid in humans.",
author = "B. Melegh and Janos Kerner and Bieber, {Loran L.}",
year = "1987",
month = "10",
day = "15",
doi = "10.1016/0006-2952(87)90318-2",
language = "English",
volume = "36",
pages = "3405--3409",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "20",

}

TY - JOUR

T1 - Pivampicillin-promoted excretion of pivaloylcarnitine in humans

AU - Melegh, B.

AU - Kerner, Janos

AU - Bieber, Loran L.

PY - 1987/10/15

Y1 - 1987/10/15

N2 - Pivampicillin treatment of seven children (five boys and two girls) for 7 days significantly reduced the amounts of total acid-soluble carnitine, free carnitine, and long-chain acylcarnitines and increased the amounts of acid-soluble acylcarnitine in plasma. The fasting plasma levels of 3-hydroxybutyrate at the end of treatment were 15% of the control value. The levels of free tatty acids were decreased, whereas triglyceride levels were unaffected, indicating impaired fat metabolism. Daily urinary excretion of total carnitine was four to five times higher than controls after the first day of treatment, although the amounts of free carnitine and acetylcarnitine were decreased. The urinary acylcarnitines were isolated and characterized by gas chromatography/electron impact mass spectrometry and fast-atom bombardment mass spectrometry. Pivaloylcarnitine was the predominant urinary acylcarnitine; it represented > 96% of the increased excretion of total carnitine and 75-80% of the total conjugated pivalic acid. The renal clearance of acylcarnitines was comparable to that of creatinine, indicating no reabsorption of pivaloylcarnitine. These data suggest a detoxification function of carnitine for pivalic acid in humans.

AB - Pivampicillin treatment of seven children (five boys and two girls) for 7 days significantly reduced the amounts of total acid-soluble carnitine, free carnitine, and long-chain acylcarnitines and increased the amounts of acid-soluble acylcarnitine in plasma. The fasting plasma levels of 3-hydroxybutyrate at the end of treatment were 15% of the control value. The levels of free tatty acids were decreased, whereas triglyceride levels were unaffected, indicating impaired fat metabolism. Daily urinary excretion of total carnitine was four to five times higher than controls after the first day of treatment, although the amounts of free carnitine and acetylcarnitine were decreased. The urinary acylcarnitines were isolated and characterized by gas chromatography/electron impact mass spectrometry and fast-atom bombardment mass spectrometry. Pivaloylcarnitine was the predominant urinary acylcarnitine; it represented > 96% of the increased excretion of total carnitine and 75-80% of the total conjugated pivalic acid. The renal clearance of acylcarnitines was comparable to that of creatinine, indicating no reabsorption of pivaloylcarnitine. These data suggest a detoxification function of carnitine for pivalic acid in humans.

UR - http://www.scopus.com/inward/record.url?scp=0023475402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023475402&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(87)90318-2

DO - 10.1016/0006-2952(87)90318-2

M3 - Article

C2 - 3675603

AN - SCOPUS:0023475402

VL - 36

SP - 3405

EP - 3409

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 20

ER -